Phase 3 N=47 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Diabetes, Type I · Diabetes, Type II · Angina
Primary: Change in Post-exercise Coronary Vasodilator Reserve — -4; 2 % change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
Phase 3 N=2,201 Occluded Artery Trial (OAT)
Cardiovascular Diseases · Heart Diseases · Myocardial Infarction
Primary: Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF) — 230; 219 participants
Phase 4 N=697 Evaluation of Integrated Cardiac Imaging in Ischemic Heart Disease
Ischemic Heart Disease
Primary: Diagnosis of IHD at Invasive Coronary Angiography and FFR Measurement — 140 participants
N/A N=443 Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions
Coronary Artery Disease
Primary: Primary Safety Endpoint: 30-Day Freedom From Major Adverse Cardiac Events (MACE) — 89.6 Percent probability of Freedom from MACE
N/A N=15 Coronary Flow Reserve Following Orbital Atherectomy
Coronary Artery Disease
Primary: Coronary Flow Reserve (CFR) — 2.23 Ratio
Phase 2 N=94 Inflammation and Coronary Endothelial Function
Coronary Artery Disease
Primary: Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE) — -1.70; 2.71; -0.39; 2.04 Percent change from rest…
Phase 4 N=30 The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina
Coronary Artery Disease
Primary: Change in Coronary Artery Flow From Rest to Isometric Handgrip (IHG) Exercise at the End of the Administration of Febuxostat and Placebo — 8.8; 10.7 mL/min — p=0.756
N/A N=900 Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64
Coronary Artery Disease
Primary: Number of Participants With Combination of All Cause Death, Non-fatal Myocardial Infarction (MI), and Hospitalization for Unstable Angina — 34; 28 Participants
N/A N=21 PET MYOCARDIAL Blood Flow Comparison to Coronary CTA and CT-FFR
Coronary Artery Disease
Primary: Number of Flow-limiting Coronary Artery Stenosis on CT — 8 Coronary arteries
N/A N=83 The Effects of Obstructive Sleep Apnea and Its Intervention on Coronary Heart Disease
Hypertension · Metabolic Disorder
Primary: Change of Daytime Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Pre-treatment and Post-treatment — -8; -3; -4; -3 mm Hg — p=<0.05
Phase 3 N=426 Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Coronary Artery Disease
Primary: Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Primary Analysis of Sensitivity Based…
N/A N=30 Single-centre, Registry Trial, the Patients Presented With Stable Coronary Artery Disease
Coronary Artery Disease
Primary: MLD SB Diameter — 08.; 1.0; 2.3; 2.2 mm
Phase 2 N=20 Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI
Myocardial Ischemia
Primary: Quantification of Myocardial Blood Volume — 3.63; 1.23 seconds^-1
Phase 3 N=478 Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Coronary Artery Disease
Primary: Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Primary Analysis of Sensitivity Based on Blinded…
N/A N=37 Comparison of Orbital Versus Rotational Atherectomy Effects On Coronary Microcirculation in PCI
Coronary Artery Disease (CAD)
Primary: Index of Microcirculatory Resistance (IMR) — 15; 25 mmHg·s
N/A N=116 COronary and MICrocirculatory Measurements in Patients With Aortic Valve Stenosis.
Aortic Stenosis · Coronary Artery Disease
Primary: FFR 6 Months After SAVR/TAVI. — -0.0279 ratio
N/A N=306 Data Acquisition for Optimization of Coronary Artery Disease (CAD) Algorithm
Coronary Artery Disease
Primary: The Area Under the Receiver Operating Characteristic Curve of the CAD-score to Separate CAD From Non-CAD Patients. — 73.4 percentage of 100
N/A N=169 Screening for Chronic Obstructive Pulmonary Disease in Patients With Acute Coronary Syndromes
Chronic Obstructive Pulmonary Disease · Acute Coronary Syndromes
Primary: COPD Diagnosis — 39 participants
N/A N=144 Coronary Artery Disease Screening in Kidney Transplant Candidates
End Stage Renal Disease · Coronary Artery Disease
Primary: Number of Participants Adhering to the Expected Number of Screening Tests — 59; 71 participants
N/A N=93 AngioSculpt® Coronary Bifurcation Study
Coronary Artery Disease · Myocardial Ischemia
Primary: Procedural Success — 91.4 percentage of participants
Phase 2 N=15 Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change in Flow Mediated Dilation — 0.26; -1.5 percentage of flow mediated dilation
Phase 4 N=54 Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow
Slow Coronary Flow · Normal, or Near Normal Coronary Angiography · Stable Angina
Primary: Angina Episode Frequnecy — 2.28; 1.68 episodes per week
N/A N=80 Genetic Determinants of the Coronary Microvascular Obstruction in PCI
Myocardial Infarction · No-Reflow Phenomenon
Primary: Hospital Mortality Rate — 6; 2 Participants
N/A N=51 PCI Alternative Using Sustained Exercise
Cardiovascular Disease
Primary: Myocardial Perfusion Reserve — 2.76; 2.47; 2.82; 2.52 Ratio
Phase 2 N=20 Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
Coronary Microvascular Dysfunction
Primary: Change From Baseline in Coronary Flow Reserve — 0.62 ratio
N/A N=200 Hybrid Coronary Revascularization Trial
Coronary Artery Disease
Primary: Major Adverse Coronary and Cerebrovascular Events (MACCE) — 0.130; 0.111 MACCE Event Rate per Person-Year
N/A N=120 Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging
Coronary Disease
Primary: Ability to Detect Stress-induced Myocardial Perfusion Abnormalities by Analysis of MDCT Images Confirmed by Coronary Angiography and/or SPECT. — 78 % accurately detected…
Phase 2 N=81 Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV
Coronary Artery Disease · Human Immunodeficiency Virus
Primary: Coronary Endothelial Function Measured by Percent Change in Coronary Blood Flow With Exercise (%) at 8 Weeks — 8.1; 13.4 Percent change from rest measurement
N/A N=100 Coronary Orbital Atherectomy System Study
CAD
Primary: Major Adverse Cardiac Event (MACE) — 85.0 Percent Probability of Freedom from MACE